Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

331 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.
Santoro MM, Bertoli A, Lorenzini P, Ceccherini-Silberstein F, Gianotti N, Mussini C, Torti C, Di Perri G, Barbarini G, Bini T, Melzi S, Caramello P, Maserati R, Narciso P, Micheli V, Antinori A, Perno CF; CARe Study Group. Santoro MM, et al. Infection. 2009 Jun;37(3):233-43. doi: 10.1007/s15010-008-8065-4. Epub 2009 Jan 23. Infection. 2009. PMID: 19169632
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, Narciso P, Antinori A, Di Perri G, Prosperi MC, Baldanti F, Micheli V, Zazzi M, Perno CF, Santoro MM; TMC114-C226 study group; ARCA study group. De Luca A, et al. Among authors: santoro mm. Antivir Ther. 2011;16(4):489-97. doi: 10.3851/IMP1799. Antivir Ther. 2011. PMID: 21685536
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection.
Scientific Coordination Committee; Marcotullio S, Andreoni M, Antinori A, d'Arminio Monforte A, Di Perri G, Galli M, Ippolito G, Perno CF, Rizzardini G, Lazzarin A; Rapporteur Committee; Cinque P, Fares G, Foglia E, Gervasoni C, Murri R, Nozza S, Rusconi S. Scientific Coordination Committee, et al. New Microbiol. 2012 Jul;35(3):259-77. Epub 2012 Jun 30. New Microbiol. 2012. PMID: 22842596 Free article. No abstract available.
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Santoro MM, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G, Callegaro A, Francisci D, Zoncada A, Maggiolo F, Zazzi M, Perno CF, Ceccherini-Silberstein F, Mussini C. Santoro MM, et al. HIV Med. 2013 Oct;14(9):571-7. doi: 10.1111/hiv.12044. Epub 2013 May 13. HIV Med. 2013. PMID: 23668660 Free article.
HEFFICON: HIV Effectiveness Italian Conference.
Antinori A, Andreoni M, Perno CF, Lazzarin A; HEFFICON Study Group. Antinori A, et al. New Microbiol. 2015 Apr;38(2):149-84. New Microbiol. 2015. PMID: 26013833 Free article.
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
Armenia D, Di Carlo D, Calcagno A, Vendemiati G, Forbici F, Bertoli A, Berno G, Carta S, Continenza F, Fedele V, Bellagamba R, Cicalini S, Ammassari A, Libertone R, Zaccarelli M, Ghisetti V, Andreoni M, Ceccherini-Silberstein F, Bonora S, Di Perri G, Antinori A, Perno CF, Santoro MM. Armenia D, et al. Among authors: santoro mm. J Antimicrob Chemother. 2017 Mar 1;72(3):855-865. doi: 10.1093/jac/dkw512. J Antimicrob Chemother. 2017. PMID: 27999048
331 results